Study S001539

A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled, Parallel Group Study With Nested Crossover Comparison to Assess the Effect of Maridebart Cafraglutide on QT/QTc Intervals in Participants Living With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07229157
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 81
Start: 2025-10-22
Primary completion: 2026-08-27
Lead sponsor: Amgen
Conditions: Overweight; Obesity
Interventions: DRUG:Maridebart Cafraglutide; DRUG:Moxifloxacin; DRUG:Placebo for Maridebart Cafraglutide; DRUG:Placebo for Moxifloxacin
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Change from Baseline in QTcF for Maridebart Cafraglutide [Up to Day 171]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.